PT-141 (Bremelanotide)
- Category
- Hormone & Sexual Health
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
PT-141 (Bremelanotide) is a synthetic melanocortin agonist marketed off-label for low libido and ED. Evidence is strongest in women with HSDD, weaker for male ED, and speculative for appetite effects. Key risks include nausea in about 40%, potentially persistent focal skin hyperpigmentation, and transient blood-pressure increases. Uncontrolled hypertension and known cardiovascular disease are contraindications. It is FDA-approved only as a branded HSDD drug for women; compounded versions are subject to pharmacy and drug laws but are not FDA-approved or reviewed before marketing for safety, effectiveness and quality.
Read Full recordStudied uses & evidence
Studied uses(6)
HSDD treatment (women)
HighFDA-approved for HSDD, backed by two replicated 24-week phase 3 randomized placebo-controlled trials.
Erectile dysfunction (men)
MediumEarly controlled studies tested both intranasal and subcutaneous PT-141 in men; use in men remains off-label.
Sexual arousal (women)
MediumSmall randomized trials suggest an effect, but phase 3 trials targeted desire, not arousal.
Evidence limits
- Evidence Level
- Level 1 — FDA Approved
43 completed studies, ~3,500 participants. Two pivotal RECONNECT Phase 3 trials (n=1,247) + 52-week extension (n=684). Phase 2 in male ED. Phase 1 weight loss. Nausea 40%, flushing 20%, headache 11%. BP +6/3 mmHg transient.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Uncontrolled hypertension
AbsoluteFDA label: causes transient blood pressure increases. Contraindicated in uncontrolled hypertension.
Cardiovascular disease
HighKnown cardiovascular disease is an absolute contraindication in the FDA label. Patients at high cardiovascular risk are a separate group for whom use is not recommended.
General cautions
Pregnancy
AbsolutePregnancy precaution: human data are insufficient, and animal studies indicate potential fetal harm. Use effective contraception and discontinue Vyleesi if pregnancy is suspected.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Nausea (40% of patients — manageable with antiemetics)
HighFlushing (20%), headache (11%)
ModerateTransient blood pressure increase (~6/3 mmHg, peaks 2-4h, resolves 12h)
ModerateFocal skin hyperpigmentation (1% with labeled use, >33% with daily use, may be permanent)
ModerateContraindicated: uncontrolled hypertension, cardiovascular disease
HighNot recommended during pregnancy
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.